Harmony Biosciences Holdings, Inc. (HRMY) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HRMY SEC filings page.
Harmony Biosciences Holdings, Inc. (HRMY) reported $868.5M in revenue for fiscal year 2025, up 21.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash generation is scaling faster than profits, while heavier investment in development and selling costs steadily compresses operating returns.
From FY2023 to FY2025, revenue increased from$582M to$868M while operating cash flow rose from$219M to$348M , showing that expansion is translating into cash rather than merely reported earnings. However, operating margin fell from33.0% to24.0% as the cost base grew faster than operating profit, so the business is funding growth with internally generated cash but retaining less profit from each sales dollar.
The balance sheet has become less debt-dependent: debt-to-equity declined from 0.4x in FY2023 to 0.2x in FY2025, while equity increased from
Reported free cash flow nearly matched operating cash flow in FY2025—
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Harmony Biosciences Holdings, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Harmony Biosciences Holdings, Inc. has an operating margin of 24.0%, meaning the company retains $24 of operating profit per $100 of revenue. This strong profitability earns a score of 92/100, reflecting efficient cost management and pricing power. This is down from 26.7% the prior year.
Harmony Biosciences Holdings, Inc.'s revenue surged 21.5% year-over-year to $868.5M, reflecting rapid business expansion. This strong growth earns a score of 84/100.
Harmony Biosciences Holdings, Inc. carries a low D/E ratio of 0.17, meaning only $0.17 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 77/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.60, Harmony Biosciences Holdings, Inc. holds $3.60 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 85/100.
Harmony Biosciences Holdings, Inc. converts 40.1% of revenue into free cash flow ($347.9M). This strong cash generation earns a score of 97/100.
Harmony Biosciences Holdings, Inc. earns a strong 18.2% return on equity (ROE), meaning it generates $18 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 90/100. This is down from 22.1% the prior year.
Harmony Biosciences Holdings, Inc. scores 5.53, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.3B) relative to total liabilities ($401.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Harmony Biosciences Holdings, Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Harmony Biosciences Holdings, Inc. generates $2.19 in operating cash flow ($348.2M OCF vs $158.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Harmony Biosciences Holdings, Inc. earns $14.23 in operating income for every $1 of interest expense ($208.5M vs $14.6M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Harmony Biosciences Holdings, Inc. generated $261.3M in revenue in Q2 2026. This represents an increase of 30.3% from the same quarter a year earlier. Against the prior quarter it is up 21.3%.
Harmony Biosciences Holdings, Inc.'s EBITDA was $95.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 76.0% from the same quarter a year earlier. Against the prior quarter it is up 120.3%.
Harmony Biosciences Holdings, Inc. reported $75.4M in net income in Q2 2026. This represents an increase of 89.6% from the same quarter a year earlier. Against the prior quarter it is up 132.2%.
Harmony Biosciences Holdings, Inc. earned $1.28 per diluted share (EPS) in Q2 2026. This represents an increase of 88.2% from the same quarter a year earlier. Against the prior quarter it is up 132.7%.
Cash & Balance Sheet
Harmony Biosciences Holdings, Inc. held $549.8M in cash against $134.0M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Harmony Biosciences Holdings, Inc.'s gross margin was 75.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 5.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.5 percentage points.
Harmony Biosciences Holdings, Inc.'s operating margin was 34.2% in Q2 2026, reflecting core business profitability. This is up 10.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 16.9 percentage points.
Harmony Biosciences Holdings, Inc.'s net profit margin was 28.9% in Q2 2026, showing the share of revenue converted to profit. This is up 9.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.8 percentage points.
Harmony Biosciences Holdings, Inc.'s ROE was 7.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 2.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.0 percentage points.
Capital Allocation
Harmony Biosciences Holdings, Inc. invested $46.6M in research and development in Q2 2026. This represents a decrease of 7.1% from the same quarter a year earlier. Against the prior quarter it is down 32.8%.
Not reported for Q2 2026.
Not reported for Q2 2026.
HRMY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $261.3M+30.3% | $215.4M+16.6% | $243.8M+21.1% | $239.5M+28.7% | $200.5M+16.0% | $184.7M+19.5% | $201.3M+19.5% | $186.0M+16.1% |
| Cost of Revenue | $63.2M+65.6% | $44.5M+39.1% | $68.5M+26.0% | $59.6M+39.4% | $38.2M+18.7% | $32.0M+16.4% | $54.4M+26.1% | $42.8M+32.5% |
| Gross Profit | $198.1M+22.0% | $170.9M+11.9% | $175.2M+19.3% | $179.8M+25.5% | $162.3M+15.4% | $152.7M+20.1% | $146.9M+17.2% | $143.3M+11.9% |
| R&D Expenses | $46.6M-7.1% | $69.4M+100.9% | $49.9M+44.0% | $55.0M+116.5% | $50.2M-21.1% | $34.5M+55.7% | $34.7M+14.4% | $25.4M+45.1% |
| SG&A Expenses | $28.1M-17.3% | $32.5M+4.0% | $57.6M+99.4% | $29.8M+4.3% | $33.9M+24.6% | $31.2M+21.7% | $28.9M+3.6% | $28.6M+26.8% |
| Operating Income | $89.3M+85.4% | $37.3M-33.7% | $38.6M-30.8% | $65.5M+6.1% | $48.2M+125.6% | $56.2M+8.1% | $55.7M+38.6% | $61.7M-4.3% |
| EBITDA | $95.3M+76.0% | $43.3M-30.5% | N/A | $71.5M+5.6% | $54.1M+97.6% | $62.2M+7.0% | $61.7M+33.2% | $67.7M-4.2% |
| Interest Expense | $3.1M-15.8% | $3.2M-15.7% | $3.5M-15.7% | $3.6M-16.7% | $3.6M-17.2% | $3.8M-15.4% | $4.2M-12.2% | $4.3M-38.0% |
| Income Tax | $17.8M+80.9% | $7.2M-38.0% | $18.3M+173.6% | $16.6M+3.4% | $9.9M-2.4% | $11.6M-13.6% | $6.7M-48.9% | $16.1M+20.2% |
| Net Income | $75.4M+89.6% | $32.5M-28.7% | $22.5M-54.6% | $50.9M+10.4% | $39.8M+243.2% | $45.6M+18.9% | $49.5M+85.9% | $46.1M+19.8% |
| EPS (Basic) | $1.30+88.4% | $0.56-29.1% | $0.40-54.0% | $0.88+8.6% | $0.69+245.0% | $0.79+16.2% | $0.87+89.1% | $0.81+26.6% |
| EPS (Diluted) | $1.28+88.2% | $0.55-29.5% | $0.39-54.1% | $0.87+10.1% | $0.68+240.0% | $0.78+16.4% | $0.85+88.9% | $0.79+25.4% |
| Diluted Shares (Avg) | 59M+0.6% | 59M+0.4% | N/A | 59M+1.1% | 58M+1.5% | 59M+1.6% | N/A | 58M-4.2% |
HRMY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B+23.9% | $1.3B+20.5% | $1.3B+27.3% | $1.2B+30.2% | $1.1B+29.1% | $1.1B+24.6% | $999.2M+23.1% | $928.1M+19.3% |
| Current Assets | $814.3M+17.8% | $778.8M+21.2% | $907.0M+56.6% | $838.8M+60.6% | $691.4M+50.8% | $642.7M+34.0% | $579.3M+28.4% | $522.4M+12.8% |
| Cash & Equivalents | $549.8M+0.7% | $589.4M+20.5% | $752.5M+66.1% | $647.0M+67.0% | $546.0M+72.1% | $489.0M+46.9% | $453.0M+45.4% | $387.4M+19.3% |
| Short-Term Investments | $118.0M+513.9% | $51.5M+186.9% | $22.8M+61.0% | $25.6M+10.7% | $19.2M-35.1% | $18.0M-54.4% | $14.2M-66.1% | $23.1M-49.8% |
| Inventory | $6.4M+4.3% | $5.3M-17.3% | $5.4M-25.6% | $6.9M-0.5% | $6.1M+8.1% | $6.4M+9.0% | $7.2M+34.2% | $6.9M+35.9% |
| Accounts Receivable | $111.0M+19.4% | $108.2M+2.1% | $96.8M+16.6% | $100.7M+23.5% | $93.0M+11.8% | $106.0M+32.9% | $83.0M+12.0% | $81.5M+21.2% |
| Long-Term Investments | $294.7M+175.4% | $229.6M+122.3% | $107.1M-1.6% | $105.8M+12.3% | $107.0M+22.7% | $103.2M+27.1% | $108.9M+50.9% | $94.2M+39.2% |
| Total Liabilities | $373.8M+11.6% | $361.5M+7.9% | $401.4M+18.0% | $373.1M+12.6% | $334.9M+4.7% | $335.0M+1.0% | $340.0M-1.3% | $331.3M+11.8% |
| Current Liabilities | $234.1M+29.9% | $217.3M+24.1% | $252.1M+44.0% | $223.4M+38.5% | $180.1M+22.9% | $175.1M+13.5% | $175.1M+6.9% | $161.3M+43.5% |
| Non-Current Liabilities | $139.8M-9.7% | $144.1M-9.9% | $149.3M-9.5% | $149.7M-12.0% | $154.8M-10.6% | $159.9M-9.8% | $165.0M-8.7% | $170.1M-7.6% |
| Long-Term Debt | $134.0M-12.6% | $138.8M-12.2% | $143.7M-11.9% | $148.5M-11.5% | $153.3M-10.5% | $158.2M-9.6% | $163.0M-8.7% | $167.8M-7.8% |
| Total Equity | $999.2M+29.3% | $910.3M+26.3% | $870.2M+32.0% | $835.1M+39.9% | $773.1M+43.5% | $720.5M+39.8% | $659.2M+41.1% | $596.8M+24.0% |
| Retained Earnings | $268.8M+207.0% | $193.4M+304.8% | $160.9M+7161.0% | $138.4M+392.9% | $87.6M+193.8% | $47.8M+145.5% | $2.2M+101.5% | -$47.3M+72.2% |
Not reported in any period shown, so not listed: Goodwill.
HRMY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $92.4M+16.5% | $27.8M-18.3% | $126.2M+67.0% | $108.7M+54.2% | $79.3M+86.1% | $34.0M+9.1% | $75.6M-1.4% | $70.5M+11.7% |
| Depreciation & Amortization | $6.0M0.0% | $6.0M0.0% | N/A | $6.0M0.0% | $6.0M-1.4% | $6.0M-2.5% | $6.0M-2.6% | $6.0M-2.3% |
| Stock-Based Compensation | $9.6M-16.0% | $10.6M-15.0% | N/A | $10.8M-5.5% | $11.4M+3.9% | $12.5M+20.3% | N/A | $11.4M+43.9% |
| Capital Expenditures | N/A | N/A | $107K-79.1% | $71K+2266.7% | $4K-99.4% | $128K+2460.0% | $513K+379.4% | $3K |
| Free Cash Flow | N/A | N/A | $126.0M+67.9% | $108.7M+54.1% | $79.3M+88.9% | $33.9M+8.7% | $75.0M-2.0% | $70.5M+11.7% |
| Investing Cash Flow | -$131.5M-571.3% | -$183.6M-7875.0% | -$17.6M-145.3% | -$4.8M-742.8% | -$19.6M+64.3% | $2.4M+138.2% | -$7.2M+80.1% | $745K+191.6% |
| Financing Cash Flow | -$558K+79.2% | -$7.2M-1950.6% | -$3.0M-10.0% | -$3.0M-155.0% | -$2.7M+22.1% | -$352K+90.3% | -$2.7M+94.9% | -$1.2M+97.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
HRMY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.8%-5.2pp | 79.3%-3.3pp | 71.9%-1.1pp | 75.1%-1.9pp | 81.0%-0.4pp | 82.7%+0.5pp | 73.0%-1.4pp | 77.0%-2.8pp |
| Operating Margin | 34.2%+10.1pp | 17.3%-13.1pp | 15.8%-11.9pp | 27.4%-5.8pp | 24.0%+11.7pp | 30.4%-3.2pp | 27.7%+3.8pp | 33.2%-7.1pp |
| Net Margin | 28.9%+9.0pp | 15.1%-9.6pp | 9.2%-15.4pp | 21.2%-3.5pp | 19.8%+13.1pp | 24.7%-0.1pp | 24.6%+8.8pp | 24.8%+0.8pp |
| Return on Equity | 7.5%+2.4pp | 3.6%-2.8pp | 2.6%-4.9pp | 6.1%-1.6pp | 5.1%+3.0pp | 6.3%-1.1pp | 7.5%+1.8pp | 7.7%-0.3pp |
| Return on Assets | 5.5%+1.9pp | 2.5%-1.8pp | 1.8%-3.2pp | 4.2%-0.8pp | 3.6%+2.2pp | 4.3%-0.2pp | 5.0%+1.7pp | 5.0%0.0pp |
| Current Ratio | 3.48-0.4x | 3.58-0.1x | 3.60+0.3x | 3.75+0.5x | 3.84+0.7x | 3.67+0.6x | 3.31+0.6x | 3.24-0.9x |
| Debt-to-Equity | 0.13-0.1x | 0.15-0.1x | 0.17-0.1x | 0.18-0.1x | 0.20-0.1x | 0.22-0.1x | 0.25-0.1x | 0.28-0.1x |
| Asset Turnover | 0.190.0x | 0.170.0x | 0.190.0x | 0.200.0x | 0.180.0x | 0.170.0x | 0.200.0x | 0.200.0x |
| FCF Margin | N/A | N/A | 51.7%+14.4pp | 45.4%+7.5pp | 39.6%+15.3pp | 18.3%-1.8pp | 37.3%-8.2pp | 37.9%-1.5pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings, Inc. HRMY | FY2025 | $868.5M | $158.7M | 18.3% | $2.3B | 88/100 |
| Sarepta Therapeutics,, Inc. SRPT | FY2025 | $2.2B | -$713.4M | -32.5% | $1.9B | 44/100 |
| Immunocore Holdings plc IMCR | FY2025 | $400.0M | -$35.5M | -8.9% | $1.5B | 65/100 |
| Mesoblast Limited MESO | FY2025 | $17.2M | -$102.1M | N/A | $1.9B | 28/100 |
| Dyne Therapeutics, Inc. DYN | FY2025 | N/A | -$446 | N/A | $3.1B | — |
| Mannkind Corporation MNKD | FY2025 | $349.0M | $5.9M | 1.7% | $1.1B | 51/100 |
Where Harmony Biosciences Holdings, Inc. Ranks
Frequently Asked Questions
What is Harmony Biosciences Holdings, Inc.'s annual revenue?
Harmony Biosciences Holdings, Inc. (HRMY) reported $868.5M in total revenue for fiscal year 2025. This represents a 21.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Harmony Biosciences Holdings, Inc.'s revenue growing?
Harmony Biosciences Holdings, Inc. (HRMY) revenue grew by 21.5% year-over-year, from $714.7M to $868.5M in fiscal year 2025.
Is Harmony Biosciences Holdings, Inc. profitable?
Yes, Harmony Biosciences Holdings, Inc. (HRMY) reported a net income of $158.7M in fiscal year 2025, with a net profit margin of 18.3%.
How much debt does Harmony Biosciences Holdings, Inc. have?
As of fiscal year 2025, Harmony Biosciences Holdings, Inc. (HRMY) had $752.5M in cash and equivalents against $143.7M in long-term debt.
What is Harmony Biosciences Holdings, Inc.'s gross margin?
Harmony Biosciences Holdings, Inc. (HRMY) had a gross margin of 77.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Harmony Biosciences Holdings, Inc.'s operating margin?
Harmony Biosciences Holdings, Inc. (HRMY) had an operating margin of 24.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Harmony Biosciences Holdings, Inc.'s net profit margin?
Harmony Biosciences Holdings, Inc. (HRMY) had a net profit margin of 18.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Harmony Biosciences Holdings, Inc.'s return on equity (ROE)?
Harmony Biosciences Holdings, Inc. (HRMY) has a return on equity of 18.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Harmony Biosciences Holdings, Inc.'s free cash flow?
Harmony Biosciences Holdings, Inc. (HRMY) generated $347.9M in free cash flow during fiscal year 2025. This represents a 59.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Harmony Biosciences Holdings, Inc.'s operating cash flow?
Harmony Biosciences Holdings, Inc. (HRMY) generated $348.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Harmony Biosciences Holdings, Inc.'s total assets?
Harmony Biosciences Holdings, Inc. (HRMY) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Harmony Biosciences Holdings, Inc.'s capital expenditures?
Harmony Biosciences Holdings, Inc. (HRMY) invested $310K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Harmony Biosciences Holdings, Inc. spend on research and development?
Harmony Biosciences Holdings, Inc. (HRMY) invested $189.6M in research and development during fiscal year 2025.
What is Harmony Biosciences Holdings, Inc.'s current ratio?
Harmony Biosciences Holdings, Inc. (HRMY) had a current ratio of 3.60 as of fiscal year 2025, which is generally considered healthy.
What is Harmony Biosciences Holdings, Inc.'s debt-to-equity ratio?
Harmony Biosciences Holdings, Inc. (HRMY) had a debt-to-equity ratio of 0.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Harmony Biosciences Holdings, Inc.'s return on assets (ROA)?
Harmony Biosciences Holdings, Inc. (HRMY) had a return on assets of 12.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Harmony Biosciences Holdings, Inc.'s P/E ratio?
Harmony Biosciences Holdings, Inc. (HRMY) trades at 12.9x earnings, its market capitalization divided by net income of $181.3M net income, trailing 12 months to June 30, 2026. The market capitalization is $2.3B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Harmony Biosciences Holdings, Inc.'s price-to-sales ratio?
Harmony Biosciences Holdings, Inc. (HRMY) trades at 2.4x sales, its market capitalization divided by revenue of $959.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.3B as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Harmony Biosciences Holdings, Inc.'s Altman Z-Score?
Harmony Biosciences Holdings, Inc. (HRMY) has an Altman Z-Score of 5.53, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Harmony Biosciences Holdings, Inc.'s Piotroski F-Score?
Harmony Biosciences Holdings, Inc. (HRMY) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Harmony Biosciences Holdings, Inc.'s earnings high quality?
Harmony Biosciences Holdings, Inc. (HRMY) has an earnings quality ratio of 2.19x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Harmony Biosciences Holdings, Inc. cover its interest payments?
Harmony Biosciences Holdings, Inc. (HRMY) has an interest coverage ratio of 14.23x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Harmony Biosciences Holdings, Inc.?
Harmony Biosciences Holdings, Inc. (HRMY) scores 88 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.